High throughput theme is all part of the process
Fine Chemicals Group: Process development symposium, 2006
 |
| Back row (L to R)
Linda Woodcock, Lee Challinor, Phillip Parker, Sean Parris, Matthew McConville. Middle (L to R) Greg Stepney, Nicola Gardner, Nathan Owston, Stephen Rowbottom, Franziska Schoenbeck. Front (L to R) Stephen Moore, Gemma Turner, Jennifer Slaughter.
Carles Giro-Manas also attended. |
The process development
symposium
meeting, organised by
SCI’s Fine Chemicals
Group and held at
Churchill College,
Cambridge, UK in
December 2006 attracted
more than 180 international
delegates and
welcomed 14 PhD students
who were able to
attend assisted by industry
bursaries.
Presentations covered
a wide range of
scientific subjects, with
talks varying from ‘academic’
to highly ‘applied’
topics. A mix of
case histories by speakers
from the pharmaceutical
industry demonstrated
how modern synthetic
methodologies and the increasing
use of enabling technologies
are being used to design processes
that continue to address
quality, economics and safety
challenges in addition to increased
focus on reducing
waste.
An emerging theme at the
meeting was the growing use of
combinatorial techniques for the
high throughput synthesis and
screening of ligands, catalysts
and conditions for applications
in asymmetric reactions. David
Ager from DSM Pharma Chemicals
discussed the use of high throughput
experimentation coupled
with fundamental mechanistic
understanding in the identification
of novel phosphoamidite
ligands and their use in asymmetric
hydrogenation and boronic
acid additions.
Following a similar theme of
high throughput experimentation,
Barry Lygo from Nottingham
University presented his work on
the identification of novel chiral
phase transfer catalysts and their
use in the synthesis of homo chiral
amino acids and natural products.
For this work Lygo, an SCI
member, received the 2006 UK
Prize for Process Chemistry
Research, sponsored by
AstraZeneca, Pf izer and
GlaxoSmithKline.
Karl Anker Jorgensen from
Aarhus University, Denmark provided
an insight into the topical
area of organocatalysis including
its use in multicomponent
reactions. In
contrast, Cranf ield
University’s Sergey Piletsky
discussed the less well
known and emerging area
of molecular imprints as
catalysts and solid phase
extractants.
The meeting set out a
number of challenges, particularly
to the pharmaceutical
industry. Frank
Montgomery looked at
how AstraZeneca is addressing
the recent concept
of design space filings
to demonstrate quality
control in the manufacture
of new active pharmaceutical
ingredients, while
Gawayne Mahboubian-
Jones from Optimal Industrial
Automation challenged the pharmaceutical
industry over why it
does not use in-line process analytical
techniques to generate real
time reaction data and demonstrate
control throughout the
whole process. Finally, Mark
Dickson of Foster Wheeler Energy
discussed continuous chemistry,
encouraging its wider application
in the pharmaceutical industry.
Alan Pettman,
Pfizer Global
Research and Development
|
